Merrimack (MACK) Q4 Loss Lower than Expected, Revenues Top

Merrimack Pharmaceuticals Inc MACK reported a loss of 21 cents per share in the fourth quarter of 2016 a penny narrower than the Zacks Consensus Estimate of a loss of 22 cents The company reported a loss of 41 cents in the year ago quarter Quarterly revenues came in at 61 2 million